christophwaltz wrote:
Well, there's a subreddit for that: https://www.reddit.com/r/EmblemCorp/new/
A summary of the company:
Q2-2018 revenues were ~$1.5M (up from $1.27M in Q1).
Emblem has a facility capable of producing ~2,000kg/year, at last count had 4,430 medical patients. They currently sell both flower and oil, and have stated they'll be starting sales of Oral Spray in partnership with DoseCann (now owned by Auxly) in Q3 this year.
They also own a medical clinic chain called GrowWise. With 18 locations, GrowWise contributed $251,000 of the latest quarterly revenues.
They invested $3M in Natura Naturals (NN) for 3,000kg/year supply, and then forwarded another $2M with a clause capable of securing another 2,000kg/year supply deal for no extra cash. They announced a LOI to acquire NN entirely, which owns a facility stated to be able to produce 15,000kg by year end 2018, and total 70,000kg by year end 2019.
They have a distribution deal in place with Shoppers Drug Mart to supply medical cannabis products (pending their license to be a licensed producer - which they have since applied for).
They invested $2.5M in Fire & Flower, a retail play, and secured a $3M/year x 5 year distribution deal with them.
They invested $1M in Compass Cannabis Clinic and secured a deal to supply their "Starbus Canada" locations.
They have a recreational distribution agreement with OCS in Ontario, and AGLC in Alberta.
They have established a joint venture (60/40 with 60% ownership in their favour) with a German pharmaceutical wholesaler Acnos Pharma GmbH to supply medical cannabis products (Acnos serves 20,000 pharmacies in Germany). First shipments expected to occur in 2019.
They have a partnership with CannTab Therapeutics to develop and distribute oral sustained release tablets within Canada. They have started production at Emblem's facility in May 2018. Expected to start selling in 2019.
They invested $2M in Greenspace Brands to develop and sell both hemp-based CBD and cannabis-based CBD products in both Canada and the USofA (each where able to under current regulations).
They also have a partnership with Strainprint for their app which allows patients to describe their experience post cannabis use, while mining the data for to refine their business.
They've launced one of their recreational brands, Symbl, in anticipation of recreational sales.
They have warrants on the market:
EMC.WT - exercise price $1.75, expire December 6 2019.
EMC.WT.A - exercise price $2.15, expire November 21 2020.
EMC.WT.B - exercise price $2.70, expire February 2 2020.
Before any recreational sales, their core medical business has been steadily improving. They are certainly worth a look.
Before any recreational sales, their core medical business has been
steadily improving. They are certainly worth a look.